Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Aprepitant in Prurigo Patients (iTAPP)
2013-000410-38Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prurigo, prurigo nodularis (PN) and prurigo simplex comparing Aprepitant gel with Placebo gel (2 arms). Primary endpoints: Change in pruritus after 4 weeks of treatment and Change in skin condition status. Started Aug 2013; status: completed.
02
Drugs
aprepitant
03
Conditions
prurigoprurigo nodularis (PN)prurigo simplex
Beyond the preview
Go deeper on 2013-000410-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000410-38.